ZA200105632B - Use of apoptosis inducing agents in the treatment of (auto)immune diseases. - Google Patents
Use of apoptosis inducing agents in the treatment of (auto)immune diseases. Download PDFInfo
- Publication number
- ZA200105632B ZA200105632B ZA200105632A ZA200105632A ZA200105632B ZA 200105632 B ZA200105632 B ZA 200105632B ZA 200105632 A ZA200105632 A ZA 200105632A ZA 200105632 A ZA200105632 A ZA 200105632A ZA 200105632 B ZA200105632 B ZA 200105632B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- cells
- delivery vehicle
- apoptin
- substance
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title claims description 71
- 238000011282 treatment Methods 0.000 title claims description 49
- 230000001939 inductive effect Effects 0.000 title claims description 40
- 208000026278 immune system disease Diseases 0.000 title claims description 29
- 210000004027 cell Anatomy 0.000 claims description 181
- 101710094856 Apoptin Proteins 0.000 claims description 120
- 241000701161 unidentified adenovirus Species 0.000 claims description 49
- 238000001476 gene delivery Methods 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 208000023275 Autoimmune disease Diseases 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 26
- 210000002437 synoviocyte Anatomy 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 230000001594 aberrant effect Effects 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 230000010415 tropism Effects 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 9
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 78
- 239000013598 vector Substances 0.000 description 45
- 239000003981 vehicle Substances 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 16
- 230000001640 apoptogenic effect Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000030833 cell death Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 102000005936 beta-Galactosidase Human genes 0.000 description 11
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- 230000004936 stimulating effect Effects 0.000 description 11
- 241000701022 Cytomegalovirus Species 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000006882 induction of apoptosis Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 241000725585 Chicken anemia virus Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000001363 autoimmune Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010023203 Joint destruction Diseases 0.000 description 4
- 238000012288 TUNEL assay Methods 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 210000001258 synovial membrane Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 231100000588 tumorigenic Toxicity 0.000 description 3
- 230000000381 tumorigenic effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 238000002738 Giemsa staining Methods 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000030570 cellular localization Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IUYLLUJNDLENRE-UHFFFAOYSA-N 2-phenylindole-2,4-diamine Chemical compound C1=C2C(N)=CC=CC2=NC1(N)C1=CC=CC=C1 IUYLLUJNDLENRE-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100037152 BAG family molecular chaperone regulator 1 Human genes 0.000 description 1
- 101710089792 BAG family molecular chaperone regulator 1 Proteins 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000027151 SOS response Effects 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99200056 | 1999-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200105632B true ZA200105632B (en) | 2002-10-09 |
Family
ID=8239795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200105632A ZA200105632B (en) | 1999-01-11 | 2001-07-09 | Use of apoptosis inducing agents in the treatment of (auto)immune diseases. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050271624A1 (da) |
| EP (1) | EP1143994B1 (da) |
| JP (1) | JP2003500336A (da) |
| AT (1) | ATE244014T1 (da) |
| AU (1) | AU3083500A (da) |
| CA (1) | CA2359392A1 (da) |
| DE (1) | DE60003632T2 (da) |
| DK (1) | DK1143994T3 (da) |
| EA (1) | EA200100770A1 (da) |
| ES (1) | ES2202039T3 (da) |
| HU (1) | HUP0200552A2 (da) |
| IL (2) | IL144228A0 (da) |
| MX (1) | MXPA01006998A (da) |
| NO (1) | NO20013397L (da) |
| PT (1) | PT1143994E (da) |
| TR (1) | TR200102713T2 (da) |
| WO (1) | WO2000041497A2 (da) |
| ZA (1) | ZA200105632B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1377667E (pt) * | 2001-03-30 | 2009-03-13 | Leadd Bv | Proteínas de fusão para o tratamento específico de cancro e doenças auto-imunitárias |
| NZ529911A (en) * | 2001-05-25 | 2008-05-30 | Nymox Corp | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| AU2002319050B2 (en) * | 2001-07-19 | 2008-09-11 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7317077B2 (en) * | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5981502A (en) * | 1990-09-12 | 1999-11-09 | Leadd B.V. | Methods and compositions for inducing apoptosis in tumor cells |
| EP0878546A1 (en) * | 1997-04-15 | 1998-11-18 | Leadd B.V. | A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin |
| US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
| ATE241808T1 (de) * | 1995-06-07 | 2003-06-15 | Leadd Bv | Verwendungen von apoptin |
| DE19704979A1 (de) * | 1996-02-07 | 1997-08-14 | Max Delbrueck Centrum | Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen |
| BR9807622A (pt) * | 1997-02-28 | 2000-02-15 | Boehringer Ingelheim Pharma | Apoptose auto-regulada de células inflamatórias por terapia de gene |
| AU736287B2 (en) * | 1997-03-21 | 2001-07-26 | Sankyo Company Limited | Humanized anti-human Fas antibody |
| JPH10324699A (ja) * | 1997-03-21 | 1998-12-08 | Sankyo Co Ltd | 抗ヒトＦａｓヒト化抗体 |
-
2000
- 2000-01-10 EP EP20000900970 patent/EP1143994B1/en not_active Expired - Lifetime
- 2000-01-10 CA CA002359392A patent/CA2359392A1/en not_active Abandoned
- 2000-01-10 PT PT00900970T patent/PT1143994E/pt unknown
- 2000-01-10 HU HU0200552A patent/HUP0200552A2/hu unknown
- 2000-01-10 EA EA200100770A patent/EA200100770A1/ru unknown
- 2000-01-10 AT AT00900970T patent/ATE244014T1/de not_active IP Right Cessation
- 2000-01-10 WO PCT/NL2000/000013 patent/WO2000041497A2/en active IP Right Grant
- 2000-01-10 DK DK00900970T patent/DK1143994T3/da active
- 2000-01-10 TR TR2001/02713T patent/TR200102713T2/xx unknown
- 2000-01-10 DE DE60003632T patent/DE60003632T2/de not_active Expired - Fee Related
- 2000-01-10 ES ES00900970T patent/ES2202039T3/es not_active Expired - Lifetime
- 2000-01-10 JP JP2000593120A patent/JP2003500336A/ja active Pending
- 2000-01-10 MX MXPA01006998A patent/MXPA01006998A/es unknown
- 2000-01-10 AU AU30835/00A patent/AU3083500A/en not_active Abandoned
- 2000-01-10 IL IL14422800A patent/IL144228A0/xx unknown
-
2001
- 2001-07-09 ZA ZA200105632A patent/ZA200105632B/en unknown
- 2001-07-09 NO NO20013397A patent/NO20013397L/no not_active Application Discontinuation
- 2001-07-10 IL IL144228A patent/IL144228A/en not_active IP Right Cessation
-
2005
- 2005-02-25 US US11/067,001 patent/US20050271624A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20013397L (no) | 2001-09-11 |
| JP2003500336A (ja) | 2003-01-07 |
| DE60003632T2 (de) | 2004-04-15 |
| WO2000041497A2 (en) | 2000-07-20 |
| EA200100770A1 (ru) | 2002-02-28 |
| ES2202039T3 (es) | 2004-04-01 |
| WO2000041497A3 (en) | 2000-09-28 |
| EP1143994A2 (en) | 2001-10-17 |
| PT1143994E (pt) | 2003-11-28 |
| IL144228A (en) | 2009-06-15 |
| CA2359392A1 (en) | 2000-07-20 |
| DK1143994T3 (da) | 2003-10-20 |
| AU3083500A (en) | 2000-08-01 |
| NO20013397D0 (no) | 2001-07-09 |
| MXPA01006998A (es) | 2002-05-06 |
| HUP0200552A2 (en) | 2002-06-29 |
| EP1143994B1 (en) | 2003-07-02 |
| TR200102713T2 (tr) | 2002-05-21 |
| IL144228A0 (en) | 2002-05-23 |
| ATE244014T1 (de) | 2003-07-15 |
| DE60003632D1 (de) | 2003-08-07 |
| US20050271624A1 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henske et al. | Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. | |
| US20080249050A1 (en) | Compounds and methods to enhance rAAV transduction | |
| US20050271624A1 (en) | Use of apoptosis inducing agents in the treatment of (auto) immune diseases | |
| JP2000515504A (ja) | 細胞死を誘導するアデノウイルスｅ４蛋白質 | |
| JPH11506340A (ja) | アポプチンの利用と方法 | |
| EP0975764B1 (en) | A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin | |
| AU2004233486B2 (en) | Use of apoptosis inducing agents in the treatment of (auto)immune diseases | |
| WO2003017763A1 (en) | Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell | |
| US7074399B2 (en) | Treatment of inflammation with p20 | |
| AU2022208384A1 (en) | Treating diseases and improving nucleic acid delivery | |
| WO2005084714A2 (en) | Raav-neprilysin compositions and methods of use | |
| US7253150B1 (en) | Gene delivery vehicle expressing the aptosis-inducing proteins VP2 and/or apoptin | |
| WO2002079222A2 (en) | Fusion proteins for specific treatment of cancer and auto-immune diseases | |
| US20090068147A1 (en) | Raav vector-based pro-opiomelanocortin compositions and methods of use | |
| US6818612B2 (en) | Use of parvovirus capsid particles in the inhibition of cell proliferation and migration | |
| US6743772B1 (en) | Use of parovirus capsid particles in the inhibition of cell proliferation and migration | |
| WO2003089467A1 (en) | Fragments of apoptin | |
| AU2566600A (en) | Use of parvovirus capsid particles in the inhibition of cell proliferation and migration | |
| JP4542732B2 (ja) | 慢性関節リウマチの判定法 | |
| MXPA97009860A (en) | Methods and uses for apopt | |
| MXPA99009486A (en) | A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin | |
| WO2011107590A1 (en) | Cnn1 (cyr61) for prevention and therapy of inflammatory disease | |
| KR20010029483A (ko) | 울혈성 심부전을 위한 유전자 치료 |